Table 1.
Demographic and Human Immunodeficiency Virus Disease Characteristics, Overall and by Death Status, of P1074 Participants, Enrolled and Followed Up at 39 Sites in the United States, 2008–2014
| Characteristica | Total (N = 1201) | Patient Status |
P Valueb | |
|---|---|---|---|---|
| Alive (n = 1173) | Died (n = 28) | |||
| Female sex, No. (%) | 623 (52) | 604 (52) | 19 (68) | .09 |
| Age (mean), SD, y | ||||
| First chart review | 17.4 (5.4) | 17.3 (5.4) | 21.3 (3.0) | <.001 |
| Last chart review | 20.9 (5.4) | 20.8 (5.4) | 23.5 (3.3) | .01 |
| Duration of study follow-up, median (IQR), y | 3.7 (2.9–4.4) | 3.7 (3.0–4.4) | 2.3 (1.2–3.0) | <.001 |
| Race/ethnicity, No. (%) | ||||
| White non-Hispanic | 136 (11) | 133 (11) | 3 (11) | .98 |
| Black non-Hispanic | 698 (58) | 681 (58) | 17 (61) | |
| Hispanic | 331 (28) | 324 (28) | 7 (25) | |
| Other or >1 race | 31 (3) | 30 (3) | 1 (4) | |
| Perinatally HIV infected, No. (%) | 1040 (87) | 1015 (87) | 25 (89) | .71 |
| BMI z score, mean (SD) | ||||
| First chart review | 0.41 (1.10) | 0.41 (1.08) | 0.22 (1.53) | .72 |
| Last chart review | 0.39 (1.15) | 0.40 (1.13) | −0.01 (1.76) | .43 |
| Change during follow-up | −0.02 (0.49) | −0.01 (0.48) | −0.24 (0.78) | .61 |
| HIV disease severity measures | ||||
| CD4 cell count, median (IQR), cells/mm3 | ||||
| First chart review | 609 (399–882) | 618 (412–886) | 28 (14–338) | <.001 |
| Last chart review | 580 (325–822) | 593 (350–828) | 20 (7–271) | <.001 |
| CD4 cell count ≤200 cells/mm3, No. (%) | ||||
| First chart review | 123 (10) | 104 (9) | 19 (68) | <.001 |
| Last chart review | 171 (14) | 151 (13) | 20 (71) | <.001 |
| CD4 cell count <200 cells/mm3 during follow-up, mean (SD), %c | 12.1 (28.2) | 10.7 (26.3) | 70.7 (43.1) | <.001 |
| CD4 cell count <350 cells/mm3 during follow-up, mean (SD), %c | 22.8 (35.8) | 21.5 (34.7) | 76.0 (39.2) | <.001 |
| HIV-1 RNA VL, median (IQR), log copies/mL | ||||
| First chart review | 1.88 (1.68–3.30) | 1.88 (1.68–3.21) | 4.59 (2.69–5.14) | <.001 |
| Last chart review | 1.68 (1.30–3.47) | 1.68 (1.30–3.37) | 4.49 (2.85–5.40) | <.001 |
| VL >1000 log copies/mL during follow-up, mean (SD), %c | 30.9 (33.4) | 29.9 (32.8) | 75.1 (28.4) | <.001 |
| ART regimen, No. (%) | ||||
| First chart review | .88 | |||
| cART | 1017 (85) | 993 (85) | 24 (86) | … |
| Non-cART ART | 70 (6) | 68 (6) | 2 (7) | … |
| No ART | 114 (10) | 112 (10) | 2 (7) | … |
| Last chart review | .02 | |||
| cART | 999 (83) | 980 (84) | 19 (68) | … |
| Non-cART ART | 83 (7) | 81 (7) | 2 (7) | … |
| No ART | 119 (10) | 112 (10) | 7 (25) | … |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; cART, combination ART (≥3 antiretroviral drugs from ≥2 drug classes); HIV, human immunodeficiency virus; IQR, interquartile range (25th–75th percentiles); SD, standard deviation; VL, viral load.
a Measures were unavailable for some characteristics, including race/ethnicity (n = 5), perinatal infection status (n = 5), BMI z score at first (n = 117) and last (n = 115) chart review, CD4 cell count at first (n = 4) and last (n = 2) chart review, and ART regimen at first (n = 22) and last (n = 11) chart review. Percentages are calculated among those with available information.
b P values comparing P1074 subjects who died with those who survived, using χ2 test for categorical measures and Wilcoxon rank sum test for continuous measures.
c Mean percentage of measurements within an individual meeting the cutoff value.